EIT KIC 2022

IMPACCT研究将研究是否有可能使用一种新的诊断测试来识别和分类脓毒症患者，这些患者具有更高的不良结局和新发感染风险。IMPACCT研究由英国帝国理工学院伦敦赞助和管理，首席研究员是Anthony Gordon教授。败血症是严重感染导致器官衰竭。这是一个重大的全球医疗保健问题。最近的研究表明，全世界每年有多达4900万例败血症病例，导致1100万人死亡。随着脓毒症护理的改善，更多的患者现在从脓毒症的早期阶段恢复，但重复发生是一个主要问题。脓毒症患者通常会经历免疫系统的减弱，称为免疫抑制。这现在被认为是大部分脓毒症患者的重要特征，并导致这些患者的预后不良。目前还没有临床试验来评估脓毒症患者的免疫功能。IMPACCT将评估一种快速的基于RNA的诊断测试，产生一个免疫分析面板（IPP）是否可以识别脓毒症患者谁是免疫抑制和不良结果的风险较高。这是一项观察性研究，未引入任何干预或新型治疗，参与时患者的标准护理和治疗未发生变化。在2年的时间里，该研究将在英国、法国和瑞典的医院招募600名患者。参与者将是正在或已经接受疑似败血症治疗并正在或已经接受器官支持的重症监护成人患者。患者将被送入ICU超过48小时，不到120小时（5天），预计需要在能够提供器官支持的环境中持续护理至少一个日历日。研究团队将收集患者在医院治疗期间的医疗状况数据，并对参与者的血液样本进行临床诊断测试。将在研究期间的3个时间点采集患者的血液样本，并将从存在的留置管线中采集。测试结果不会与研究团队共享，也不会影响患者的护理。将在入选后90天联系患者，以完成有关其健康状况和任何新感染的日记。

The IMPACCT study will investigate whether it is possible to use a new diagnostic test to identify and classify patients with sepsis who are at higher risk of poor outcomes and developing new infections. The IMPACCT study is being sponsored and managed by Imperial College London in the UK and the Chief Investigator is Professor Anthony Gordon. Sepsis is when severe infection leads to organ failure. It is a major global healthcare problem. Recent studies suggest as many as 49 million cases of sepsis worldwide each year leading to 11 million deaths. As sepsis care has improved more patients now recover from the early phases of sepsis but repeat occurrences are a major problem. Patients with sepsis often experience weakening of their immune systems known as immune suppression. This is now recognised as an important feature in a large proportion of patients who have sepsis and it leads to poor outcomes for these patients. At present there is no clinical test to assess the immune function of patients who have sepsis. IMPACCT will evaluate if a rapid RNA-based diagnostic test that produces an Immune Profiling Panel (IPP) can identify patients with sepsis who are immunosuppressed and at higher risk of poor outcomes. It is an observational study with no intervention or novel treatment introduced and no change to patients’ standard care and treatment when taking part. Over a 2-year period, the study will recruit 600 patients in hospitals in the UK, France, and Sweden.Participants will be adult patients in intensive care who are being, or have been, treated for suspected sepsis and are receiving, or have received, organ support. The patients will have been admitted to an ICU for over 48hours and less than 120 hours (5 days) and are expected to require ongoing care in an environment capable of providing organ support for at least one more calendar day. The study research team will collect data on the patient’s medical condition throughout their treatment in hospital and will conduct a clinical diagnostic test on participants’ blood samples. Blood samples will be taken from patients at 3 time points during the study and will be taken from indwelling lines where present. Test results will not be shared with the research team or influence patients’ care. Patients will be contacted 90 days after inclusion to complete a diary regarding their wellbeing and any new infections.